Technology | August 11, 2010

New Vascular Access Catheter Sizes Expand Treatable Patient Population

August 11, 2010 – New sizes of the SoloPath TransFemoral Endovascular Access Catheter were recently cleared by the U.S. Food and Drug Administration (FDA). The new sizes provide the potential to treat a larger patient population.

The device allows access to the larger vascular anatomy at a relatively small catheter size and is then expanded to provide a conduit for the delivery of larger diameter devices. It offers a percutaneous delivery method for large femoral/iliac artery stent grafts, aortic stent grafts and percutaneous heart valves.

A major clinical market for the SoloPath catheter is in the delivery of stent grafts for the treatment of aortic aneurysms (AAA stent grafts). These stent grafts require large catheter delivery systems. They are implanted minimally invasively as a substitute for conventional open surgical procedures to treat ruptured aneurysms.

The annual market for such stent grafts is approximately $400 million and growing 20 percent per year.

The SoloPath Controlled Deployment Technology (CDT) is a different approach to procedures requiring minimally invasive access to remote sites within the body. The SoloPath enters the body at approximately one-half the diameter of conventional access sheaths, is very flexible and provides superior navigation through the vascular anatomy.

Once in position, the device is deployed utilizing radial expansion to expand the sheath and remodel the tissue/vasculature in order to provide unrestricted access for the delivery of therapeutic devices. Early studies indicate that this Controlled Deployment Technology can allow the physician to perform an easy, one-step access procedure that can potentially reduce vascular/tissue trauma and virtually eliminate the need for other pre-operative steps (e.g., vascular stenting), which are often required for access with conventional devices.

The SoloPath allows minimally invasive access in a manner that is potentially less traumatic to the arterial vasculature compared to devices currently in use. By eliminating a number of surgical maneuvers, use of the SoloPath may reduce procedural time, surgical expense and patient recovery time.

For more information: www.onsetmedical.com

Related Content

The researchers used high resolution cross-sectional imaging with CT or MRI to assess 225 men with abdominal aortic aneurysm. Follow-up lasted, on average, more than three years.  Slightly more than half of patients had an intraluminal thrombus. The aneurysms of those with intraluminal thrombus were larger at baseline and grew by a rate of 2 mm per year, twice as fast as the 1 mm per year growth rate in people without intraluminal thrombus.
News | Endovascular Aortic Repair | January 29, 2020
January 29, 2020 – The presence of a blood clot on the wall of the aorta in people with...
The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch.  #VIVA19 #VIVA2019

The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch. 

News | Endovascular Aortic Repair | November 11, 2019
November 7, 2019 — The Endospan Ltd.
Obese Patients Have More Post-Op Problems Following AAA Repair
News | Endovascular Aortic Repair | November 21, 2018
New research in the December edition of the Journal of Vascular Surgery suggests significant increase in morbidities in...
FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall
News | Endovascular Aortic Repair | October 08, 2018
Endologix Inc. received notice that the U.S. Food and Drug Administration (FDA) has classified a voluntary recall...
The Gore TAG stent graft used in TEVAR aortic repair procedures for aneurysms.

The Gore TAG stent graft used for endovascular aortic aneurysm repair procedures.

Feature | Endovascular Aortic Repair | February 05, 2018 | Andrei Churyla, M.D., S. Chris Malaisrie, M.D.
Here are several considerations for physicians when choosing...
Endologix Receives IDE Approval for EVAS2 Confirmatory Clinical Study
News | Endovascular Aortic Repair | October 19, 2017
Endologix Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA...
New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair
News | Endovascular Aortic Repair | May 23, 2017
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and...
abdominal aortic aneurysm, AAA, gender differences, women vs. men, endovascular repair, Journal of Vascular Surgery study
News | Endovascular Aortic Repair | April 05, 2017
Following repair of abdominal aortic aneurysms (AAA), women appear to have more unfavorable outcomes than men in terms...
Beaumont Hospital, Michigan, endovascular aortic repair, EVAR, conscious sedation
News | Endovascular Aortic Repair | July 08, 2016
Kirk Schoenherr, 56, of Clinton Township, Mich., recently became just the second patient at Beaumont Hospital, Royal...